Skip to main content
SpringerLink
Log in

Stem Cell Transplantation for Pediatric ALL

  • Chapter
  • First Online:
Pediatric Acute Lymphoblastic Leukemia

Abstract

For pediatric ALL with the highest risk of relapse, allogeneic stem cell transplantation (allo-SCT) is performed as the most potent form of consolidation therapy. Considering acute and late complication, allo-SCT should be limitedly indicated for cases with extremely high risk cytogenetic/genomic alterations or very poor response to treatment (including early relapsed cases). If available, human leukocyte antigen (HLA) matched siblings are the best donor, but current studies showed comparable outcomes of allo-SCT from HLA matched unrelated donors or cord blood for pediatric ALL. In terms of conditioning regimen, total body irradiation (TBI)-based myeloablative combination is still the most potent and widely used as a standard therapy for ALL in children aged 1 years or older, while busulfan-based conditioning is the standard for infant ALL. Considering acute and late complication caused by TBI, reduction or avoidance of TBI should be continuously challenged.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stern M, de Wreede LC, Brand R, et al. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia. 2014;28:2235–40.

    Article  CAS  PubMed  Google Scholar 

  2. Kato M, Kurata M, Kanda J, et al. Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia. Bone Marrow Transplant. 2019;54:68–75.

    Article  PubMed  Google Scholar 

  3. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998–1006.

    Article  CAS  PubMed  Google Scholar 

  4. Arico M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28:4755–61.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27:5175–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13:936–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children's oncology group trial AALL0622. J Clin Oncol. 2018;36:2306–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007;110:1112–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Schultz KR, Devidas M, Bowman WP, et al. Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from children's oncology group study AALL0031. Leukemia. 2014;28:964–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Oliansky DM, Camitta B, Gaynon P, et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. Biol Blood Marrow Transplant. 2012;18:505–22.

    Article  CAS  PubMed  Google Scholar 

  11. McNeer JL, Devidas M, Dai Y, et al. Hematopoietic stem-cell transplantation does not improve the poor outcome of children with hypodiploid acute lymphoblastic leukemia: a report from children's oncology group. J Clin Oncol. 2019;37:780–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Pui CH, Rebora P, Schrappe M, et al. Outcome of children with hypodiploid acute lymphoblastic leukemia: a retrospective multinational study. J Clin Oncol. 2019;37:770–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Pui CH, Gaynon PS, Boyett JM, et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002;359:1909–15.

    Article  PubMed  Google Scholar 

  14. Kosaka Y, Koh K, Kinukawa N, et al. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Blood. 2004;104:3527–34.

    Article  CAS  PubMed  Google Scholar 

  15. Jacobsohn DA, Hewlett B, Morgan E, Tse W, Duerst RE, Kletzel M. Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:999–1005.

    Article  PubMed  Google Scholar 

  16. Dreyer ZE, Dinndorf PA, Camitta B, et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's oncology group. J Clin Oncol. 2011;29:214–22.

    Article  CAS  PubMed  Google Scholar 

  17. Mann G, Attarbaschi A, Schrappe M, et al. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 study. Blood. 2010;116:2644–50.

    Article  CAS  PubMed  Google Scholar 

  18. Mouttet B, Vinti L, Ancliff P, et al. Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica. 2019;104:e244–7.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zhang X, Inukai T, Hirose K, et al. Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors. Leukemia. 2012;26:2483–93.

    Article  CAS  PubMed  Google Scholar 

  20. Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012;366:1371–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206–14.

    Article  CAS  PubMed  Google Scholar 

  22. Eckert C, Henze G, Seeger K, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013;31:2736–42.

    Article  PubMed  Google Scholar 

  23. Messina C, Cesaro S, Rondelli R, et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in Italy. AIEOP/FONOP-TMO group. Italian association of paediatric haemato-oncology. Bone Marrow Transplant. 1998;21:1015–21.

    Article  CAS  PubMed  Google Scholar 

  24. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2015;21:1863–9.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175–81.

    Article  CAS  PubMed  Google Scholar 

  26. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the histocompatibility and alternate stem cell source working committee of the international bone marrow transplant registry. J Clin Oncol. 2004;22:4872–80.

    Article  PubMed  Google Scholar 

  27. Shinzato A, Tabuchi K, Atsuta Y, et al. PBSCT is associated with poorer survival and increased chronic GvHD than BMT in Japanese paediatric patients with acute leukaemia and an HLA-matched sibling donor. Pediatr Blood Cancer. 2013;60:1513–9.

    Article  PubMed  Google Scholar 

  28. Keesler DA, St Martin A, Bonfim C, Seber A, Zhang MJ, Eapen M. Bone marrow versus peripheral blood from unrelated donors for children and adolescents with acute leukemia. Biol Blood Marrow Transplant. 2018;24:2487–92.

    Article  PubMed  PubMed Central  Google Scholar 

  29. American Academy of Pediatrics. Committee on, B. Children as hematopoietic stem cell donors. Pediatrics. 2010;125:392–404.

    Article  Google Scholar 

  30. Sakaguchi H, Watanabe N, Matsumoto K, et al. Comparison of donor sources in hematopoietic stem cell transplantation for childhood acute leukemia: a nationwide retrospective study. Biol Blood Marrow Transplant. 2016;22:2226–34.

    Article  PubMed  Google Scholar 

  31. Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33:1265–74.

    Article  CAS  PubMed  Google Scholar 

  32. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369:1947–54.

    Article  PubMed  Google Scholar 

  33. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood. 2001;97:2962–71.

    Article  CAS  PubMed  Google Scholar 

  34. Wagner JE Jr, Eapen M, Carter S, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014;371:1685–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–86.

    Article  CAS  PubMed  Google Scholar 

  36. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Sugita J, Kawashima N, Fujisaki T, et al. HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning. Biol Blood Marrow Transplant. 2015;21:1646–52.

    Article  PubMed  Google Scholar 

  38. Berger M, Lanino E, Cesaro S, et al. Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies: an AIEOP-GITMO retrospective multicenter study. Biol Blood Marrow Transplant. 2016;22:902–9.

    Article  CAS  PubMed  Google Scholar 

  39. Dietrich S, Finel H, Martinez C, et al. Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. Leukemia. 2016;30:2086–9.

    Article  CAS  PubMed  Google Scholar 

  40. Bertaina A, Zecca M, Buldini B, et al. Unrelated donor vs HLA-haploidentical alpha/beta T-cell- and B-cell-depleted HSCT in children with acute leukemia. Blood. 2018;132:2594–607.

    Article  CAS  PubMed  Google Scholar 

  41. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000;18:340–7.

    Article  CAS  PubMed  Google Scholar 

  42. Kebriaei P, Anasetti C, Zhang MJ, et al. Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24:726–33.

    Article  CAS  PubMed  Google Scholar 

  43. Kato M, Takahashi Y, Tomizawa D, et al. Comparison of intravenous with oral busulfan in allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimens for pediatric acute leukemia. Biol Blood Marrow Transplant. 2013;19:1690–4.

    Article  CAS  PubMed  Google Scholar 

  44. Koh K, Tomizawa D, Moriya Saito A, et al. Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia. Leukemia. 2015;29:290–6.

    Article  CAS  PubMed  Google Scholar 

  45. Brochstein JA, Kernan NA, Groshen S, et al. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. N Engl J Med. 1987;317:1618–24.

    Article  CAS  PubMed  Google Scholar 

  46. Gassas A, Sung L, Saunders EF, Doyle JJ. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Bone Marrow Transplant. 2006;38:739–43.

    Article  CAS  PubMed  Google Scholar 

  47. Kato M, Ishida H, Koh K, et al. Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: a study from the pediatric ALL working group of the Japan Society for Hematopoietic Cell Transplantation. Pediatr Blood Cancer. 2015;62:1844–50.

    Article  CAS  PubMed  Google Scholar 

  48. Tracey J, Zhang MJ, Thiel E, Sobocinski KA, Eapen M. Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2013;19:255–9.

    Article  PubMed  Google Scholar 

  49. Fujino H, Ishida H, Iguchi A, et al. High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS). Int J Hematol. 2019;109:578–83.

    Article  PubMed  Google Scholar 

  50. Kato K, Kato M, Hasegawa D, et al. Comparison of transplantation with reduced and myeloablative conditioning for children with acute lymphoblastic leukemia. Blood. 2015;125:1352–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Transplantation and Cell Therapy, Children’s Cancer Center, National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan

    Motohiro Kato

Authors
  1. Motohiro Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Motohiro Kato .

Editor information

Editors and Affiliations

  1. Department of Transplantation and Cell Therapy, Children’s Cancer, Center National Center for Child Health and Development, Setagaya-ku, Tokyo, Japan

    Motohiro Kato

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kato, M. (2020). Stem Cell Transplantation for Pediatric ALL. In: Kato, M. (eds) Pediatric Acute Lymphoblastic Leukemia. Springer, Singapore. https://doi.org/10.1007/978-981-15-0548-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-0548-5_15

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-0547-8

  • Online ISBN: 978-981-15-0548-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation